- India
- /
- Life Sciences
- /
- NSEI:DCAL
Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings
Even though Dishman Carbogen Amcis Limited's (NSE:DCAL) recent earnings release was robust, the market didn't seem to notice. Investors are probably missing some underlying factors which are encouraging for the future of the company.
See our latest analysis for Dishman Carbogen Amcis
How Do Unusual Items Influence Profit?
Importantly, our data indicates that Dishman Carbogen Amcis' profit was reduced by ₹146m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Dishman Carbogen Amcis took a rather significant hit from unusual items in the year to March 2022. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
An Unusual Tax Situation
Having already discussed the impact of the unusual items, we should also note that Dishman Carbogen Amcis received a tax benefit of ₹223m. This is meaningful because companies usually pay tax rather than receive tax benefits. Of course, prima facie it's great to receive a tax benefit. And since it previously lost money, it may well simply indicate the realisation of past tax losses. However, the devil in the detail is that these kind of benefits only impact in the year they are booked, and are often one-off in nature. Assuming the tax benefit is not repeated every year, we could see its profitability drop noticeably, all else being equal. While we think it's good that the company has booked a tax benefit, it does mean that there's every chance the statutory profit will come in a lot higher than it would be if the income was adjusted for one-off factors.
Our Take On Dishman Carbogen Amcis' Profit Performance
In its last report Dishman Carbogen Amcis received a tax benefit which might make its profit look better than it really is on a underlying level. Having said that, it also had a unusual item reducing its profit. Given the contrasting considerations, we don't have a strong view as to whether Dishman Carbogen Amcis's profits are an apt reflection of its underlying potential for profit. If you want to do dive deeper into Dishman Carbogen Amcis, you'd also look into what risks it is currently facing. You'd be interested to know, that we found 2 warning signs for Dishman Carbogen Amcis and you'll want to know about them.
In this article we've looked at a number of factors that can impair the utility of profit numbers, as a guide to a business. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:DCAL
Dishman Carbogen Amcis
Provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide.
Slightly overvalued with imperfect balance sheet.